

1 **Loss of Factor H family proteins associates with meningococcal disease severity**

2 Anna E. van Beek<sup>1,2,\*,#</sup>, Richard B. Pouw<sup>1,2,3,\*</sup>, Victoria J. Wright<sup>4</sup>, Neneh Sallah<sup>5</sup>, David Inwald<sup>4</sup>, Clive  
3 Hoggart<sup>4</sup>, Mieke C. Brouwer<sup>1</sup>, Rachel Galassini<sup>4</sup>, John Thomas<sup>6</sup>, Leo Calvo-Bado<sup>6</sup>, Colin Fink<sup>6</sup>, Ilse Jongerius<sup>1,2</sup>,  
4 Martin Hibberd<sup>5</sup>, Diana Wouters<sup>1,†</sup>, Michael Levin<sup>4</sup>, Taco W. Kuijpers<sup>2,7,§</sup>, on behalf of the EUCLIDS  
5 consortium.

6 <sup>1</sup> Sanquin Research, Department of Immunopathology, and Landsteiner Laboratory, Amsterdam University  
7 Medical Centre, Amsterdam Infection and Immunity Institute, Amsterdam, the Netherlands

8 <sup>2</sup> Department of Pediatric Immunology, Rheumatology, and Infectious Diseases, Emma Children's Hospital,  
9 Amsterdam University Medical Centre, Amsterdam, the Netherlands

10 <sup>3</sup> Department of Pharmaceutical Sciences, Molecular Pharmacy group, University of Basel, Basel, Switzerland

11 <sup>4</sup> Section for Paediatric Infectious Disease, Department of Infectious Disease, Faculty of Medicine, Imperial  
12 College London, United Kingdom

13 <sup>5</sup> Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and  
14 Tropical Medicine, London, United Kingdom

15 <sup>6</sup> Micropathology Ltd, University of Warwick, United Kingdom

16 <sup>7</sup> Sanquin Research, Department of Blood Cell Research, and Landsteiner Laboratory, Amsterdam University  
17 Medical Centre, Amsterdam, the Netherlands

18 \* these authors contributed equally to this work

19 # Current address: Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health  
20 Institute, Basel, Switzerland

21 † Current address: Centre for Infectious Disease Control, National Institute for Public Health and the  
22 Environment, Bilthoven, the Netherlands

23 § To whom correspondence may be addressed: [t.w.kuijpers@amsterdamumc.nl](mailto:t.w.kuijpers@amsterdamumc.nl).

24 **Short title:** Factor H family proteins and meningococcal disease severity

25 **ABSTRACT (149 words)**

26 *Neisseria meningitidis*, the causative agent of meningococcal disease (MD), evades complement-mediated  
27 clearance upon infection by 'hijacking' the human complement regulator factor H (FH). The FH protein family  
28 also comprises the homologous FH-related (FHR) proteins, hypothesized to act as antagonists of FH, and FHR-3  
29 has recently been implicated to play a major role in MD susceptibility. Here, we show that, next to FH and FHR-  
30 3, the circulating levels of all FH family proteins are equally decreased during pediatric MD. We did not observe  
31 a specific consumption of FH or FHR-3 by *N. meningitidis* during the first days of infection and the levels  
32 recovered over time. MD severity associated predominantly with a loss of FH. Strikingly, loss of FH and FHRs  
33 associated strongly with renal failure, suggesting insufficient protection of host tissue by the FH protein family.  
34 Retaining higher levels of FH family proteins may thus limit tissue injury during MD.

## 35 INTRODUCTION

36 *Neisseria meningitidis* is a Gram-negative commensal bacterium carried in the nasopharynx by up to 24% of the  
37 population [1]. Upon infection, it can cause meningococcal meningitis and/or septicemia, collectively called  
38 meningococcal disease (MD). MD is a severe, debilitating and life-threatening disease with an occurrence of 2 –  
39 20 per 100,000 in developed countries [2,3]. The complement system plays a major role in preventing MD,  
40 exemplified by deficiencies in components of its terminal pathway that are associated with recurrent *N.*  
41 *meningitidis* infection [4,5].

42 *N. meningitidis* is known to exploit human complement regulator factor H (FH) to avoid complement-mediated  
43 clearance [6,7]. FH is a glycoprotein circulating in plasma at around 300 µg/mL [8]. It is the major regulator of  
44 the alternative pathway and is composed of 20 complement control protein (CCP) domains. FH is crucial in  
45 protecting human cells from complement-mediated damage and contains two regions involved in the binding to  
46 human cells, located in CCP6 to CCP8 and in CCP19 and CCP20 [9]. *N. meningitidis* expresses various proteins  
47 to recruit FH to its surface [6,7,10–12]. FH-binding protein (fHbp) plays a dominant role in evading  
48 complement-mediated clearance upon infection [13]. This lipoprotein binds FH at CCP6 and CCP7, while  
49 leaving the complement regulatory capabilities of FH intact [14]. The ‘hijacking’ of FH aids *N. meningitidis* in  
50 avoiding complement-mediated clearance, prolonging its survival in human circulation [6,7,15].

51 The FH protein family is encoded in tandem in the *CFH-CFHR* locus. *CFH* encodes FH and its short splice  
52 variant, FH like-1 (FHL-1), while the five *CFHR* genes encode the homologs FH-related (FHR)-1, FHR-2, FHR-  
53 3, FHR-4A and FHR-5 [16]. FHR-1, FHR-2 and FHR-5 circulate in blood as dimers, with FHR-1 and FHR-2  
54 also forming heterodimers [17,18]. The FHRs have high sequence identity to the ligand binding regions of FH  
55 (CCP6-8 and CCP19-20), but lack CCP domains homologous to FH CCP1-4, which are involved in complement  
56 regulation [19,20]. Therefore, FHRs are hypothesized to compete with FH binding to cellular surfaces,  
57 enhancing complement activation [16].

58 A previous genome-wide association study identified that, apart from SNPs in *CFH*, gene variations in *CFHR3*  
59 were also found to associate with MD susceptibility [21]. This was the first indication that the FHRs might play  
60 a role in MD, with FHR-3 as the most promising candidate to compete with FH. FHR-3 has the highest sequence  
61 identity with FH CCP6 and CCP7 (91% and 85%, respectively), and was found to bind to fHbp in vitro,  
62 competing with FH for binding [22].

63 Since we recently developed FHR-specific ELISAs, we were now able to make the translation from genetics and  
64 in vitro data towards the study of FH family proteins and their levels during the acute stage of MD. We  
65 previously reported that the levels of FHRs are 10 – 100 fold lower in comparison to FH during steady-state  
66 [8,18,23]. However, the levels of FH and the FHRs may very well be altered during an episode of acute MD,  
67 possibly affecting their ratio and changing the balance of alternative pathway activation and regulation.

68 In this study, we analyzed the serum levels of FH and all FHRs from a cohort of pediatric MD patients during  
69 the acute stage of disease in relation to *N. meningitidis* serogroup, diagnosis and severity parameters and  
70 compared these with levels during convalescence in surviving patients. We report here that not only FH and  
71 FHR-3, but plasma concentrations of all FH family proteins are greatly decreased during the acute phase of MD.  
72 However, predominantly low FH plasma concentrations are associated with the severity of MD.

73

## 74 RESULTS

### 75 Study cohort

76 Serum samples were available from 106 children with MD (**Table 1**). The patient age ranged from 0.1 – 16 years  
77 at admission with a median age of 2.9 years with equal gender distribution. Convalescent samples were drawn 10  
78 – 2011 days after infection, with a median of 65 days. Acute stage samples were obtained at the first or second  
79 day of hospitalization. In seventeen patients, samples were also obtained during subsequent days. Fourteen  
80 patients (13%) were diagnosed with localized meningococcal meningitis, 75 (71%) with meningococcal  
81 septicemia, and seventeen (16%) with both (i.e. proven septicemia and meningitis). Fifteen out of the 106  
82 patients did not survive. Death occurred at a median of one day (range 0 – 11). *N. meningitidis* serogroup was  
83 successfully typed in 69 cases, with serogroup B being the most prevalent (43 cases, 61%), followed by  
84 serogroup C (24 cases, 34%) and single cases of serogroup A and W135.

85 **Table 1 | Patient characteristics**

Number of female cases (%)	52 (49%)
Median age (y) at admission (IQR)	2.9 (1.3 – 7.9)
Median time interval (days) of convalescence sample drawn after	65 (49 – 78)
Cases of meningococcal meningitis (%)	14 (13%)
Cases of meningococcal septicemia (%)	75 (71%)
Cases of meningococcal septicemia and meningitis (%)	17 (16%)

86 Characteristics of pediatric MD cohort of 106 patients. IQR: interquartile range

87

88 **FH and FHR protein levels decrease equally during MD**

89 We assessed the levels of FH and all FHRs in the first sample drawn at the acute stage and at convalescence  
 90 from MD patients, using in-house developed ELISAs (**Figure 1a and 1b**) [8,18,23]. FH, FHR-1/1, FHR-1/2,  
 91 FHR-2/2 and FHR-5 levels at convalescence were comparable to those of healthy children (**Table 2**) [24]. Levels  
 92 of FHR-3 and FHR-4A were found to be higher at convalescence than FHR-3 and FHR-4A levels in healthy  
 93 children. Two children appeared to carry a homozygous *CFHR3/CFHR1* deletion, as evidenced by the lack of  
 94 either protein in their convalescent sample. No apparent *CFHR3/CFHR1* deletion was found among the non-  
 95 survivors, based on their acute stage FHR-3 and FHR-1/1 levels.

96 At the acute stage, both FH and all FHRs were markedly decreased, with median levels 50-64% lower than  
 97 found at convalescence (**Figure 1, Table 2**). In contrast to all other FH family proteins, the acute stage FHR-4A  
 98 levels, while being significantly decreased compared to those found at convalescence, were not significantly  
 99 lower compared to the normal range found in healthy children. The relative decreases of all FH family proteins  
 100 strongly correlated with each other, indicating a similar underlying mechanism (**Figure 1c and 1d**). Of note, the  
 101 FH and FHR ELISAs were not affected by the possible presence of circulating fHbp in the acute samples  
 102 (**Supplementary Figure 1**).

103

104 **Table 2 | FH protein family ranges during MD**

Protein (µg/mL)	Reference interval (RI)	Convalescent level MD patients	Mann-Whitney test ( <i>p</i> value) (RI vs conv.)	Acute level MD patients	Decrease (median)	Mann-Whitney test ( <i>p</i> value) (conv. vs acute)
<b>FH</b>	282 (238 – 326)	295 (234 – 320)	0.8056	131 (109-181)	56%	< 0.0001
<b>FHR-1/1</b>	11.36 (7.39 – 14.26)	11.85 (7.50 – 14.48)	0.7445	5.59 (3.96 – 8.07)	53%	< 0.0001
<b>FHR-1/2</b>	5.40 (3.92 – 7.01)	5.39 (3.99 – 6.90)	0.9624	2.59 (1.81 – 3.53)	52%	< 0.0001
<b>FHR-2/2</b>	0.64 (0.40 – 1.11)	0.78 (0.41 – 0.98)	0.9316	0.28 (0.19 – 0.47)	64%	< 0.0001
<b>FHR-3</b>	0.57 (0.38 – 0.80)	0.69 (0.48 – 0.98)	0.0074	0.30 (0.20 – 0.50)	57%	< 0.0001
<b>FHR-4A</b>	0.91 (0.48 – 1.50)	2.16 (1.35 – 3.46)	<0.0001	1.07 (0.63 – 1.49)	50%	< 0.0001
<b>FHR-5</b>	1.23 (0.92 – 1.47)	1.23 (0.92 – 1.55)	0.9956	0.58 (0.37 – 0.88)	53%	< 0.0001

105 Reference intervals (RIs) as previously described for 110 healthy Dutch children [24]. RIs and convalescent  
106 levels of MD patients of FHR-1/1, FHR-1/2, FHR-2/2 and FHR-3 exclude the non-detectable levels of those who  
107 presumably carry the homozygous *CFHR3/CFHR1* deletion. All protein levels depict median and interquartile  
108 range (IQR) in  $\mu\text{g/mL}$ . Mann-Whitney tests describe test between the RIs vs convalescent levels and between  
109 convalescent levels vs during the acute stage.

110

### 111 **FH family proteins show different kinetics following the acute stage of infection.**

112 After having established that all FH family proteins were decreased proportionally during the acute phase of  
113 infection, we investigated the changes in concentration on subsequent days in a subset of seventeen patients. In  
114 contrast to the equal decrease upon infection, recovery of the FH family proteins in the subsequent days differed  
115 from each other (**Figure 2a and 2b**). The median FH levels remained low during the first days of hospitalization,  
116 but showed a sign of recovery to normal levels at day four. In contrast, levels of FHR-1/1, FHR-1/2, FHR-2/2  
117 and FHR-3 showed a quicker recovery. FHR-4A levels did not change during the first four days of  
118 hospitalization, remaining at approximately 50% of convalescent levels. Blood levels of FHR-5 recovered more  
119 steadily, similar to FH. The decrease in serum levels at the acute stage of MD was not unique to the FH family  
120 proteins, since total IgG levels, which were measured as a reference protein of similar molecular weight as FH,  
121 showed a similar decrease and dynamics (**Figure 2c**) [25].

### 122 **FH and FHR levels associate with clinical and laboratory parameters**

123 Next, we analyzed whether the low FH and FHR levels at the acute stage were related to the classification or  
124 severity of MD. Levels of FH, FHR-1/1, FHR-1/2, FHR-3 and FHR-4A were lower in patients diagnosed with  
125 septicemia in comparison to those with meningitis alone (**Figure 3**). Levels of FHR-2/2 were comparable  
126 between the patient groups, while FHR-5 levels were lower in patients who were diagnosed with septicemia  
127 alone when compared to meningococcal meningitis with accompanying septicemia (**Figure 3**).

128 We also assessed whether the FH and FHR levels at acute stage correlated with the clinical parameters WCC,  
129 platelet count, aPTT, INR, fibrinogen, CRP, potassium, base excess, lactate, the severity scores PIM and  
130 GMSPS, and the bacterial load (**Table 3, Figure 4**). Overall, all correlations indicated a negative effect of low  
131 acute stage FH and/or FHR levels, i.e. low protein levels correlating with more adverse clinical values. Acute  
132 stage FH levels correlated with most clinical parameters, with only potassium, lactate and the PIM score  
133 showing no significant correlation with FH. Of the FHRs, FHR-1 and FHR-5 correlated most with various  
134 clinical parameters. There was a striking correlation between low levels of all FH family proteins and base  
135 excess. Although reduced base excess correlated with increased lactate levels in the patients ( $r = -0.56, p <$

136 0.0001) the FH family protein levels were not correlated with lactate. Although both base excess and lactate are  
137 markers of impaired perfusion and shock, the correlation with base excess and not with lactate may have been  
138 influenced by the increase in base excess associated with resuscitation with high chloride-containing fluids  
139 (normal saline or 5% albumin), which cause a worsening of base excess due to hyperchloremic acidosis [26]. FH  
140 family protein levels were lowest in those patients receiving renal support (**Figure 5, Supplementary Figure 2**).

141 **Table 3 | Clinical and laboratory parameters**

Parameter	Normal		MD patients
		<i>n</i>	Median (IQR)
WCC (*10 <sup>9</sup> /L)	4.0 – 11.0	105	9.3 (3.7 – 23.5)
Platelet count	150 – 400	105	196 (132 – 256)
aPTT (s)	30 – 40	99	45.9 (36 – 61.9)
INR	0.8 – 1.2	94	1.6 (1.3 – 1.8)
Fibrinogen (g/L)	1.5 – 4.0	84	3.1 (1.9 – 4.5)
CRP (mg/L)	5 – 10	93	92 (54 – 157)
Potassium (mM/L)	3.5 – 5.0	103	3.5 (3.2 – 3.9)
Base Excess (mEq/L)	-2 – 2	104	-7 (-10 – -5)
Lactate (mmol/L)	0.5 – 1	56	1.6 (0.9 – 3.7)
PIM	0	100	4.9 (2.4 – 14.0)
GMSPS	0	106	10 (7 – 12)

142 *n*: number of informative cases; IQR: interquartile range.

143

144 Acute stage levels FH, FHR-1/1, FHR-1/2, FHR-4A and FHR-5 correlated with bacterial load, which is a well-  
145 established marker of MD severity (**Figure 4**). We determined the *N. meningitidis* bacterial load in 62 patients of  
146 whom sufficient acute stage serum was available. The bacterial load ranged from 8.52\*10<sup>0</sup> to 1.04\*10<sup>9</sup> copies  
147 per mL serum (median = 5.68\*10<sup>4</sup>). We did not observe a difference between serogroups B and C in bacterial  
148 load ( $p = 0.33$ , Mann-Whitney test), nor did we observe a difference in severity (by PIM score,  $p = 0.26$ , Mann-  
149 Whitney test). Except for FHR-5, we did not observe a significant association between *N. meningitidis*  
150 serogroups B or C and acute stage FH family protein levels (**Supplementary Figure 3**). Bacterial load correlated  
151 negatively with base excess ( $r = -0.42$ ,  $p < 0.001$ ) and positively with lactate ( $r = 0.68$ ,  $p < 0.0001$ ).

152

## 153 **DISCUSSION**

154 The role of complement in MD is complex and can be regarded as a “double-edged sword”. While its activation  
155 is essential for the clearance of invading microbes, too much complement activation may contribute to

156 immunopathology. Plasma levels of FH are subjected to a similarly delicate balance: High FH levels protect host  
157 tissues from complement-mediated damage, but this also increases survival of FH-binding pathogens such as *N.*  
158 *meningitidis*. In contrast, low FH levels decrease complement evasion of FH-binding pathogens but renders host  
159 tissue more vulnerable to complement-mediated damage. This delicate balance in FH levels is further  
160 complicated by the presence of the proposed FH antagonists, the FHRs. It is hypothesized that the competition  
161 between FH and the FHRs determines to what extent and at what rate alternative pathway activation takes place  
162 on surfaces [16]. With the recent insight that fHbp also binds FHR-3, it was suggested that the levels of FHR-3  
163 determine if *N. meningitidis* successfully recruits FH and evades complement, and thereby would play a crucial  
164 role in developing MD [22]. Our previous research demonstrated that a systemic competition between FH and  
165 FHR-3 is unlikely to occur during steady-state, where the molar excess of FH is ~130-fold compared with FHR-  
166 3 [8]. However, it was unknown up until now whether this would also hold true during MD.

167 Although FH and possibly FHR-3 play an important role in MD susceptibility, the dynamics of their plasma  
168 levels during the acute stage of MD were unknown. By measuring all FH family protein levels during MD in the  
169 first days after admission, we observed that the protein levels of both FH and the FHRs were markedly decreased  
170 during the acute stage of MD, whereas their recovery towards normal levels showed different kinetics. FH and  
171 FHR-5 levels slowly progressed to normal levels, suggesting a low synthesis rate of these proteins by the liver,  
172 or alternatively, that their consumption or loss from the circulation may be prolonged. FHR-1, FHR-2 and FHR-  
173 3 showed quicker recoveries within a few days after admission, while FHR-4A did not recover during the first  
174 four days. As the main production site of the FH protein family is the liver, the various observed recovery rates  
175 indicate that liver synthesis is not generally low during MD.

176 During the acute stage of MD, necrotic or damaged tissue, including the vasculature, will activate complement  
177 [27,28]. The reduction of FH and the FHRs in the circulation may therefore be due to the subsequent recruitment  
178 of these proteins to sites of complement activation. Alternatively, it can be hypothesized that the protein levels  
179 are low because of additional passive leakage into the tissues due to increased vascular permeability [29]. Both  
180 processes could account for the lower protein levels during the acute stage of meningococcal septicemia, which  
181 is a more systemic disease in comparison to meningococcal meningitis. In support of the increased vascular  
182 permeability as an underlying mechanism, the serum levels of IgG (of similar molecular weight as FH) were also  
183 decreased, suggesting a non-selective disappearance of proteins from the blood compartment. This is in line with  
184 clinical vascular leakage and edema formation known to occur during treatment at the early stage of the disease.  
185 If vascular leakage would be accounting completely for the initial loss of proteins, similar recovery rates are



186 expected. However, the FH protein family showed different dynamics in subsequent days, suggesting that other  
187 processes are at play. We could not determine whether their different dynamics are reflecting different roles for  
188 each of the proteins during inflammatory responses or are due to different rates of synthesis.

189 Finally, FH levels could be low due to recruitment via fHbp on the meningococci. However, this was also  
190 observed for FHRs that are not bound by *N. meningitidis*. Moreover, the observed decreases of all FH family  
191 proteins correlated strongly with each other and were reduced to a similar extent as IgG. This suggests that the  
192 reduced plasma concentrations are due to general leakage from the circulation rather than consumption due to  
193 binding on meningococci.

194 FHR-3 is the only FHR bound by fHbp that can compete with FH in vitro and might affect *N. meningitidis*  
195 survival [22]. However, its acute stage protein levels did not correlate with bacterial load. The vastly different  
196 molar concentrations of FH and FHR-3, with FH circulating at a >100-fold excess compared to FHR-3, make it  
197 unlikely that substantial amounts of FHR-3 would be bound by meningococci, and that this would be reflected in  
198 plasma levels. The proposed role of FHR-3 as competitor of FH in meningococcal disease therefore is unlikely  
199 to play a role in the circulation.

200 Of the FH protein family, FH was found to correlate most with MD severity parameters. Lower FH levels during  
201 the acute stage correlated with the prediction score GMSPS as well as the blood variables which are known to be  
202 associated with MD severity, including WCC, platelets, base excess, INR and aPTT. The correlation of FH with  
203 coagulation markers such as fibrinogen, INR and aPTT is in line with a previous study that showed decreased  
204 levels of FH when sepsis was accompanied by disseminated intravascular coagulation [30], and corroborates an  
205 in vitro study that suggests a potential role for FH in coagulation [31]. The association of FH with severity also  
206 explains the observed association of FH and FHRs with bacterial load. While, as discussed above, this is unlikely  
207 to reflect consumption, bacterial load is a strong predictor of severity, and thus the associations with FH and  
208 FHRs are suggestive of FH and FHR clearance due to severe inflammation and the accompanying complement  
209 activation [32,33].

210 Low levels of most FH family proteins were associated with renal failure during hospitalization. While this may  
211 be part of the association of reduced FH and FHRs with disease severity, regulation of complement activation by  
212 FH is known to be involved in renal disease including hemolytic uremic syndrome and glomerulonephritis [16].  
213 The association of FH and FHRs with impaired kidney function may not simply be due to disease severity, but  
214 rather may indicate a specific protective role of the FH family proteins in preventing renal injury.

215 The double activity of FH, protecting both host tissue and meningococci against complement-mediated damage,  
216 makes analysis of its role in MD challenging. Following what has previously been found in vitro for *N.*  
217 *meningitidis* [15], where small changes in FH levels greatly affect survival, we propose that a balanced  
218 concentration of FH in blood is key in MD. Low steady-state FH levels may reduce susceptibility towards MD,  
219 but if MD does occur, the low FH levels may be insufficient to protect the vasculature and kidneys from  
220 complement-mediated damage [34]. Indeed, it has previously been shown that inhibition of complement  
221 improves survival of mice suffering from bacterial meningitis [35]. Therapeutic interventions that substantially  
222 increase the levels of FH activity on host surfaces (and not on microbial surfaces) may reduce tissue injury, when  
223 administered as soon as patients have been treated with antibiotics to eliminate meningococci from the  
224 circulation. A potentiating antibody that increases the function of FH on host surfaces without enhancing binding  
225 to meningococci might therefore be worth investigating in acute stages of systemic inflammation [34].

226

## 227 **MATERIALS and METHODS**

### 228 **Study cohort**

229 Patients in this study (n = 106) were a subset of the cohort recruited at St. Mary's Hospital, London (UK)  
230 between 1992 and 2003, the details of which have been reported previously [15,21,36–38]. All samples were  
231 obtained with informed consent of the parents or guardians of each patient according to the local ethics  
232 committee and the Declaration of Helsinki and were stored at -80 until use. Cases included in this study had  
233 microbiologically confirmed MD and had acute serum samples taken during hospitalization, and a serum sample  
234 taken after convalescence (in survivors, n = 91).

### 235 **Blood Markers of disease severity**

236 White cell count (WCC), platelet count, activated partial thromboplastin time (aPTT), international normalized  
237 ratio (INR), base excess, and levels of fibrinogen, C-reactive protein (CRP), potassium, and lactate were all  
238 determined as part of routine diagnostics at St. Mary's Hospital, London (UK). Glasgow Meningococcal  
239 Septicemia Prognostic Score (GMSPS) and Pediatric Index of Mortality (PIM) score were determined as  
240 previously described [39,40].

### 241 **Measurement FH and FHR proteins in serum**

242 FH family proteins and total human IgG levels in serum were determined by in-house developed ELISAs as  
243 previously described [8,18,23,25]. In short, FH was measured by ELISA using an in-house generated, specific  
244 mouse monoclonal antibody (mAb) directed against CCP domains 16/17 of FH (clone anti-FH.16, Sanquin  
245 Research, Amsterdam, the Netherlands) as the capture mAb and polyclonal goat anti-human FH (Quidel, San  
246 Diego, CA, USA), which was HRP-conjugated in-house, as the detecting Ab. FHR-1/1 homodimers and FHR-  
247 1/2 heterodimers were captured using clone anti-FH.02 (Sanquin Research), and detected with biotinylated anti-  
248 FH.02 (Sanquin Research) or anti-FHR-2 (clone MAB5484, R&D Systems, Minneapolis, MN, USA),  
249 respectively. For the specific detection of FHR-3, an in-house developed mAb directed against FHR-3 and FHR-  
250 4A (clone anti-FHR-3.1, Sanquin Research) was used as the capture mAb. A biotinylated mAb directed against  
251 FHR-3 and FH (clone anti-FHR-3.4, Sanquin Research) was used as detecting mAb. To measure FHR-4A, a rat  
252 anti-mouse kappa mAb (RM-19, Sanquin Research) was coated on the plate before addition of the capture mAb  
253 (clone anti-FHR-4A.04, Sanquin Research), capturing specifically FHR-4A. The detecting mAb was a  
254 biotinylated polyclonal rabbit anti-human FHR-3 (Sanquin Research). FHR-5 was measured by using two  
255 specific mAbs: anti-FHR-5.1 as a capturing mAb and biotinylated anti-FHR-5.4 as detection mAb (both from  
256 Sanquin Research).

257 To determine whether fHbp affects the measurement of FH and FHRs by ELISA, *e.g.* by sterically hindering or  
258 otherwise affecting specific antibody binding to FH or any of the FHRs, the ELISAs were performed as  
259 described above, with purified fHbp (a kind gift of Prof. Christoph Tang, University of Oxford, UK) added  
260 during the sample step. A concentration of 100 µg/mL fHbp was used relative to 100% serum, representing an  
261 approximate 1-to-1 molar ratio with FH, using fHbp wildtype variants 1 and 3, as well as the fHbp variant 1  
262 mutant that is unable to bind FH.

### 263 ***N. meningitidis* quantification**

264 Three sets of primers/probes widely used in molecular diagnostics laboratories targeting three different  
265 conserved genes (*metA*, *sodC* and *tauE*) in *N. meningitidis* were used for bacterial load quantification by qPCR.  
266 Master mixes (LightCycler® 480 II Master mix, 2X conc., Cat. nr. 04887301001, Roche, Basel, Switzerland)  
267 contained 2.5 µL primers (200 nM), 2.5 µL probe (100 nM) and 20 µL template DNA in a total reaction volume  
268 of 50 µL, following manufacturer's recommendations. Initial denaturation of 95°C for 7 minutes was followed  
269 by 50 cycles of 95°C for 10 s, 60°C for 40 s, and 72°C for 1 s and a final cooling step at 40°C for 10 s.  
270 Quantification was estimated using *N. meningitidis* DNA Standards copies/µL (dilution series of  $1.15 \times 10^{-6}$  to

271 1.15x10<sup>-3</sup>) AMPLIRUN<sup>®</sup> DNA Control (1.15x10<sup>-7</sup> copies/μL. Amplification data were analyzed by instrument  
272 software (Roche).

273 **Statistical analysis**

274 Data were analyzed using GraphPad Prism, version 8 (GraphPad software, La Jolla, CA, USA) and R version  
275 3.5.0 [41].

276

277 **FUNDING**

278 Research leading to these results has received funding from Meningitis Research Foundation and Imperial  
279 College BRC, and the European Union's seventh Framework program under EC-GA no. 279185 (EUCLIDS;  
280 [www.euclids-project.eu](http://www.euclids-project.eu)). The funders had no role in study design, data collection and analysis, decision to  
281 publish, or preparation of the manuscript.

282 **ACKNOWLEDGMENTS**

283 The authors would like to thank the patients participating in the study.

284 **CONFLICT OF INTEREST DISCLOSURE**

285 RP, MB, DW and TK are co-inventors of patents describing the potentiation of FH with monoclonal antibodies  
286 and therapeutic uses thereof. All other authors declare no relevant conflict of interest.

287

288 **Contact information corresponding author:** Amsterdam UMC, Prof. Dr. Taco. Kuijpers, Meibergdreef 9,  
289 1105 AZ Amsterdam, the Netherlands.

290 **REFERENCES**

- 291 1. Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic  
292 review and meta-analysis. *Lancet Infect Dis.* 2010;10: 853–861. doi:10.1016/S1473-3099(10)70251-6
- 293 2. Borrow R, Alarcón P, Carlos J, Caugant DA, Christensen H, Debbag R, et al. The Global Meningococcal  
294 Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of  
295 herd protection. *Expert Rev Vaccines.* 2016; 1–16. doi:10.1080/14760584.2017.1258308
- 296 3. Sridhar S, Greenwood B, Head C, Plotkin SA, Sáfadi MA, Saha S, et al. Global incidence of serogroup  
297 B invasive meningococcal disease: a systematic review. *Lancet.* 2015;15: 1334–1346.
- 298 4. Kuijpers TW, Nguyen M, Hopman CTP, Nieuwenhuys E, Dewald G, Lankester AC, et al. Complement  
299 factor 7 gene mutations in relation to meningococcal infection and clinical recurrence of meningococcal  
300 disease. *Mol Immunol.* 2010;47: 671–677. doi:10.1016/j.molimm.2009.10.017
- 301 5. Schejbel L, Fadnes D, Permin H, Tore K, Garred P, Mollnes TE. Primary complement C5 deficiencies –  
302 Molecular characterization and clinical review of two families. *Immunobiology.* 2013;218: 1304–1310.
- 303 6. Madico G, Welsch JA, Lewis LA, McNaughton A, Perlman DH, Costello CE, et al. The meningococcal  
304 vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum  
305 resistance. *J Immunol.* 2006;177: 501–510. doi:10.4049/jimmunol.177.1.501
- 306 7. Schneider MC, Exley RM, Chan H, Feavers I, Kang Y, Sim RB, et al. Functional significance of factor  
307 H binding to *Neisseria meningitidis*. *J Immunol.* 2006;176: 7566–7575.
- 308 8. Pouw RB, Brouwer MC, Geissler J, van Herpen L V, Zeerleder SS, Wuillemin WA, et al. Complement  
309 factor H-related protein 3 serum levels are low compared to factor H and mainly determined by gene  
310 copy number variation in CFHR3. *PLoS One.* 2016;11: e0152164. doi:10.1371/journal.pone.0152164
- 311 9. Schmidt CQ, Herbert AP, Kavanagh D, Gandy C, Fenton CJ, Blaum BS, et al. A new map of  
312 glycosaminoglycan and C3b binding sites on factor H. *J Immunol.* 2008;181: 2610–2619.
- 313 10. Lewis LA, Ngampasutadol J, Wallace R, Reid JEA, Vogel U, Ram S. The meningococcal vaccine  
314 candidate neisserial surface protein a (NspA) binds to factor H and enhances meningococcal resistance to  
315 complement. *PLoS Pathog.* 2010;6: e1001027. doi:10.1371/journal.ppat.1001027
- 316 11. Lewis LA, Vu DM, Vasudhev S, Shaughnessy J, Granoff DM, Ram S. Factor h-dependent alternative

- 317 pathway inhibition mediated by porin B contributes to virulence of *Neisseria meningitidis*. *MBio*.  
318 2013;4: 1–9. doi:10.1128/mBio.00339-13
- 319 12. Giuntini S, Pajon R, Ram S, Granoff DM. Binding of Complement Factor H to PorB3 and NspA  
320 Enhances Resistance of *Neisseria meningitidis* to Anti-Factor H Binding Protein Bactericidal Activity.  
321 *Infect Immun*. 2015;83: 1536–1545. doi:10.1128/IAI.02984-14
- 322 13. Loh E, Kugelberg E, Tracy A, Zhang Q, Gollan B, Ewles H, et al. Temperature triggers immune evasion  
323 by *Neisseria meningitidis*. *Nature*. 2013;502: 1–6. doi:10.1038/nature12616
- 324 14. Schneider MC, Prosser BE, Caesar JJE, Kugelberg E, Li S, Zhang Q, et al. *Neisseria meningitidis*  
325 recruits factor H using protein mimicry of host carbohydrates. *Nature*. 2009;458: 890–893.  
326 doi:10.1038/nature07769
- 327 15. Haralambous E, Dolly SO, Hibberd ML, Litt DJ, Udalova I a, O’dwyer C, et al. Factor H, a regulator of  
328 complement activity, is a major determinant of meningococcal disease susceptibility in UK Caucasian  
329 patients. *Scand J Infect Dis*. 2006;38: 764–771. doi:10.1080/00365540600643203
- 330 16. Sánchez-Corral P, Pouw RB, López-Trascasa M, Józsi M. Self-damage caused by dysregulation of the  
331 complement alternative pathway: Relevance of the factor H protein family. *Front Immunol*. 2018;9:  
332 1607. doi:10.3389/fimmu.2018.01607
- 333 17. Goicoechea de Jorge E, Caesar JJE, Malik TH, Patel M, Colledge M, Johnson S, et al. Dimerization of  
334 complement factor H-related proteins modulates complement activation in vivo. *Proc Natl Acad Sci U S*  
335 *A*. 2013;110: 4685–4690. doi:10.1073/pnas.1219260110
- 336 18. van Beek AE, Pouw RB, Brouwer MC, van Mierlo G, Ooijevaar-de Heer P, de Boer M, et al. Factor H-  
337 related (FHR)-1 and FHR-2 form homo- and heterodimers, while FHR-5 circulates only as homodimer  
338 in human plasma. *Front Immunol*. 2017;8: 1328. doi:10.3389/fimmu.2017.01328
- 339 19. Kühn S, Skerka C, Zipfel PF. Mapping the complement regulatory domains in the human factor H-Like  
340 protein 1 and in factor H. *J Immunol*. 1995;155: 5663–5670.
- 341 20. Gordon DL, Kaufman RM, Blackmore TK, Kwong J, Lublin DM. Identification of complement  
342 regulatory domains in human factor H. *J Immunol*. 1995;155: 348–356.
- 343 21. Davila S, Wright VJ, Khor CC, Sim KS, Binder A, Breunis WB, et al. Genome-wide association study

- 344 identifies variants in the CFH region associated with host susceptibility to meningococcal disease. *Nat*  
345 *Genet.* 2010;42: 772–776. doi:10.1038/ng.640
- 346 22. Caesar JJE, Lavender H, Ward PN, Exley RM, Eaton J, Chittock E, et al. Competition between  
347 antagonistic complement factors for a single protein on *N. meningitidis* rules disease susceptibility. *Elife.*  
348 2014;3: e04008. doi:10.7554/eLife.04008
- 349 23. Pouw RB, Brouwer MC, Beek AE Van, Józsi M, Wouters D, Kuijpers TW. Complement factor H-  
350 related protein 4A is the dominant circulating splice variant of CFHR4. *Front Immunol.* 2018;9: 729.  
351 doi:10.3389/fimmu.2018.00729
- 352 24. van Beek AE, Kamp A, Kruithof S, Nieuwenhuys EJ, Wouters D, Jongerius I, et al. Reference intervals  
353 of factor H and factor H-related proteins in healthy children. *Front Immunol.* 2018;9: 1727.  
354 doi:10.3389/fimmu.2018.01727
- 355 25. van de Bovenkamp FS, Derksen NIL, Ooijevaar-de Heer P, van Schie KA, Kruithof S, Berkowska MA,  
356 et al. Adaptive antibody diversification through N-linked glycosylation of the immunoglobulin variable  
357 region. *Proc Natl Acad Sci.* 2018;115: 1901–1906. doi:10.1073/pnas.1711720115
- 358 26. Levin M, Cunnington AJ, Wilson C, Nadel S, Lang HJ, Ninis N, et al. Effects of saline or albumin fluid  
359 bolus in resuscitation: evidence from re-analysis of the FEAST trial. *Lancet Respir Med.* 2019;7: 581–  
360 593. doi:10.1016/S2213-2600(19)30114-6
- 361 27. Brandtzaeg P, Mollnes TE, Kierulf P. Complement Activation and Endotoxin Levels in Systemic  
362 Meningococcal Disease. *J Infect Dis.* 1989;160: 58–65.
- 363 28. Huson MAM, Wouters D, Van Mierlo G, Grobusch MP, Zeerleder SS, Van Der Poll T. HIV Coinfection  
364 Enhances Complement Activation during Sepsis. *J Infect Dis.* 2015;212: 474–483.  
365 doi:10.1093/infdis/jiv074
- 366 29. Oragui EE, Nadel S, Kyd P, Levin M. Increased excretion of urinary glycosaminoglycans in  
367 meningococcal septicemia and their relationship to proteinuria. *Crit Care Med.* 2000;28: 3002–3008.  
368 doi:10.1097/00003246-200008000-00054
- 369 30. Higgins SJ, De Ceunynck K, Kellum JA, Chen X, Gu X, Chaudhry SA, et al. Tie2 protects the  
370 vasculature against thrombus formation in systemic inflammation. *J Clin Invest.* 2018;128: 1471–1484.



- 371           doi:10.1172/JCI97488
- 372    31.    Ferluga J, Kishore U, Sim RB. A potential anti-coagulant role of complement factor H. *Mol Immunol.*  
373           2014;59: 188–193. doi:10.1016/j.molimm.2014.02.012
- 374    32.    Darton T, Guiver M, Naylor S, Jack DL, Kaczmarski EB, Borrow R, et al. Severity of meningococcal  
375           disease associated with genomic bacterial load. *Clin Infect Dis an Off Publ Infect Dis Soc Am.* 2009;48:  
376           587–594. doi:10.1016/S0734-3299(09)79329-3
- 377    33.    Hackett S, Guiver M, Marsch J, Sills J, Thomson A, Kaczmarski E, et al. Meningococcal bacterial DNA  
378           load at presentation correlates with disease severity. *Arch Dis Child.* 2002;86: 44–46.  
379           doi:<http://dx.doi.org/10.1136/adc.86.1.44>
- 380    34.    Pouw RB, Brouwer MC, de Gast M, van Beek AE, van den Heuvel LP, Schmidt CQ, et al. Potentiation  
381           of complement regulator factor H protects human endothelial cells from complement attack in aHUS  
382           sera. *Blood Adv.* 2019;3: 621–632. doi:10.1182/bloodadvances.2018025692
- 383    35.    Kasanmoentalib ES, Valls Seron M, Morgan BP, Brouwer MC, van de Beek D. Adjuvant treatment with  
384           dexamethasone plus anti-C5 antibodies improves outcome of experimental pneumococcal meningitis: A  
385           randomized controlled trial. *J Neuroinflammation.* 2015;12: 1–7. doi:10.1186/s12974-015-0372-y
- 386    36.    Hibberd ML, Sumiya M, Summerfield JA, Booy R, Levin M, The Meningococcal Research Group.  
387           Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal  
388           disease. *Lancet.* 1999;353: 1049–1053. doi:S0140673698083500 [pii]
- 389    37.    Haralambous E, Weiss HA, Radalowicz A, Hibberd ML, Booy R, Levin M. Sibling familial risk ratio of  
390           meningococcal disease in UK Caucasians. *Epidemiol Infect.* 2003;130: 413–418.
- 391    38.    Wright V, Hibberd M, Levin M. Genetic polymorphisms in host response to meningococcal infection:  
392           The role of susceptibility and severity genes. *Vaccine.* 2009;27: B90–B102.  
393           doi:10.1016/j.vaccine.2009.05.002
- 394    39.    Sinclair JF, Skeoch CH, Hallworth D. Prognosis of meningococcal septicaemia. *Lancet.* 1987;2: 38.
- 395    40.    Pollack MM, Patel KM, Ruttimann UE. PRISM III: An updated pediatric risk of mortality score. *Crit*  
396           *Care Med.* 1996;24: 743–752.
- 397    41.    R Core Team. R: a language and environment for statistical computing. In: R Foundation for Statistical

398 Computing, Vienna, Austria [Internet]. Vienna, Austria; 2015. Available: <http://www.r-project.org/>

399

400 **Figure 1 | FH family protein levels are low at the acute stage of MD. (a,b)** Differences in FH, FHR-1/1  
401 homodimers, FHR-1/2 heterodimers, FHR-2/2 homodimers, FHR-3, FHR-4A and FHR-5 homodimers as  
402 assessed at the acute stage (samples obtained during the first or second day of hospitalization,  $n = 106$ ) compared  
403 to levels at convalescence ( $n = 91$ ). Two children appeared to carry a homozygous *CFHR3/CFHR1* deletion, as  
404 evidenced by the lack of either protein in their convalescent sample. They were excluded from the analysis for  
405 FHR-1/1, FHR-1/2, FHR-2/2 and FHR-3 ( $n = 104$  and  $n = 89$  for acute stage and convalescence). Acute serum  
406 samples comprised 88 samples drawn at day 1 and 18 samples drawn at day 2 of hospitalization, for patients of  
407 whom no day 1 sample was available. Levels of FHR-2/2 were calculated based on FHR-1/1 and FHR-1/2  
408 levels. Shaded area indicates 95% range in healthy patients, with dashed line indicating the median. Scatter dot  
409 plots depict median and interquartile range (IQR) as red lines. Statistical significance was tested using a Mann-  
410 Whitney test. (c) Correlations ( $r$ ) between the relative decreases of FH family proteins (ratios between acute and  
411 convalescent levels, by dividing acute levels over convalescent levels) were assessed using Pearson's measure of  
412 association, followed by the Benjamini-Hochberg procedure to control for the false discovery rate (FDR, set to  
413 0.05). Blue shades indicate, from light to dark:  $p < 0.05$ ;  $p < 0.01$ ;  $p < 0.001$ ; and  $p < 0.0001$ . (d) Examples of  
414 correlations in (c), showing relative decrease in FH levels versus relative decrease in FHR levels. A:C ratio:  
415 acute:convalescent ratio; Conv.: convalescent.

416 **Figure 2 | FH family protein level dynamics during the acute stage of MD. (a)** FH family protein levels in  
417 paired samples ( $n = 17$ ) as assessed during the first four days of infection (day 1 until day 4), compared with the  
418 concentration at convalescence (C). Shaded area indicates 95% range in healthy patients, with dashed line  
419 indicating the median. Friedman test followed by Dunn's multiple comparisons test, with every acute stage  
420 dataset compared to the levels found at convalescence. \*\*\*\*:  $p < 0.0001$ ; \*\*\*:  $p < 0.001$ ; \*\*:  $p < 0.01$ ; \*:  $p <$   
421  $0.05$ ; ns = not significant. (b) FH family protein levels as in (a), normalized to the levels found at convalescence.  
422 (c) Total IgG levels in unpaired samples (maximum  $n = 16$ ) as assessed during the first four days of infection  
423 and at convalescence. The 95% range in healthy patients is not depicted, due to variability of total IgG levels  
424 during childhood. Lines depict median and IQR.

425 **Figure 3 | FH family proteins per clinical syndrome.** Protein levels of FH, FHR-1/1, FHR-1/2, FHR-3, FHR-  
426 4A and FHR-5 at the acute stage (first sample obtained during hospitalization,  $n = 106$ ), according to the  
427 diagnosed clinical syndrome: meningococcal meningitis (M,  $n = 14$ ), meningococcal septicemia (S,  $n = 75$ ), or  
428 both (M+S,  $n = 17$ ). Statistical significance was tested using a Kruskal-Wallis test, followed by a Dunn's  
429 multiple comparisons test. Lines depict median and IQR. \*\*:  $p < 0.01$ ; \*:  $p < 0.05$ ; ns = not significant.

430 **Figure 4 | Associations of acute stage FH family protein levels with clinical and laboratory parameters.**

431 Pearson correlation coefficients ( $r$ ), considering twelve severity markers and seven FH family proteins  
432 (including the different dimers). Correlations were assessed using Pearson's measure of association, followed by  
433 the Benjamini-Hochberg procedure to control for the false discovery rate (FDR, set to 0.05). Blue shades  
434 indicate, from light to dark:  $p < 0.05$ ;  $p < 0.01$ ;  $p < 0.001$ ; and  $p < 0.0001$ . WCC: white cell count; aPTT:  
435 activated partial thromboplastin time; INR: international normalized ratio; CRP: C-reactive protein; PIM:  
436 pediatric index of mortality; GMSPS: Glasgow Meningococcal Septicemia Prognostic Score.

437 **Figure 5 | FH family proteins are low in patients who receive renal support.** Serum levels of FH, FHR-1/1,  
438 FHR-1/2, FHR-2/2, FHR-3, FHR-4A and FHR-5 at the acute stage of patients who did ( $n = 15$ ) or did not ( $n =$   
439 90) receive renal support. Both surviving and non-surviving patients are included here. Statistical significance  
440 was tested using a Mann-Whitney test. Lines depict median and IQR. \*\*\*\*:  $p < 0.0001$ ; \*\*\*:  $p < 0.001$ ; \*\*:  $p <$   
441 0.01; \*:  $p < 0.05$ ; ns = not significant.











